Cargando…

Parthenolide plays a protective role in the liver of mice with metabolic dysfunction-associated fatty liver disease through the activation of the HIPPO pathway

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a serious threat to human health. Parthenolide (PAR) displays several important pharmacological activities, including the promotion of liver function recovery during hepatitis. The aim of the present study was to assess the effect of PA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Weihong, He, Yukai, Liu, Qiuli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127053/ https://www.ncbi.nlm.nih.gov/pubmed/33955510 http://dx.doi.org/10.3892/mmr.2021.12126

Ejemplares similares

Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease
por: Ramanathan, Raghu, et al.
Publicado: (2022)

Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
por: Subramanian, Pallavi, et al.
Publicado: (2022)

The Hippo-Yes Association Protein Pathway in Liver Cancer
por: Jie, Lu, et al.
Publicado: (2013)

Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
por: Han, A Lum
Publicado: (2022)

Role of the Hippo pathway in liver regeneration and repair: recent advances
por: Pibiri, Monica, et al.
Publicado: (2022)

The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease
por: Martín-Mateos, Rosa, et al.
Publicado: (2021)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus
por: Miyake, Teruki, et al.
Publicado: (2022)

Linking Extracellular Matrix Agrin to the Hippo Pathway in Liver Cancer and Beyond
por: Chakraborty, Sayan, et al.
Publicado: (2018)

Activation of Hippo signaling pathway mediates mitochondria dysfunction and dilated cardiomyopathy in mice
por: Wu, Wei, et al.
Publicado: (2021)

Mitochondrial depletion of glutaredoxin 2 induces metabolic dysfunction-associated fatty liver disease in mice
por: Scalcon, Valeria, et al.
Publicado: (2022)

A novel SLC25A1 inhibitor, parthenolide, suppresses the growth and stemness of liver cancer stem cells with metabolic vulnerability
por: Zhang, Zhichun, et al.
Publicado: (2023)

Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update
por: Alharthi, Jawaher, et al.
Publicado: (2022)

Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions
por: Lee, Jung Il
Publicado: (2022)

Therapeutic developments in metabolic dysfunction-associated fatty liver disease
por: Shi, Yiwen, et al.
Publicado: (2022)

Cardiometabolic characterization in metabolic dysfunction–associated fatty liver disease
por: Perdomo, Carolina M., et al.
Publicado: (2022)

Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
por: Jung, Han Na, et al.
Publicado: (2023)

De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation
por: Han, Ma Ai Thanda, et al.
Publicado: (2021)

Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
por: Lim, Tae Seop, et al.
Publicado: (2023)

Intragastric Safflower Yellow Alleviates HFD Induced Metabolic Dysfunction-Associated Fatty Liver Disease in Mice through Regulating Gut Microbiota and Liver Endoplasmic Reticulum Stress
por: Hu, Wenjing, et al.
Publicado: (2023)

Comparative effects of the herbal constituent parthenolide (Feverfew) on lipopolysaccharide-induced inflammatory gene expression in murine spleen and liver
por: Smolinski, Alexa T, et al.
Publicado: (2005)

Hippo pathway coactivators Yap and Taz are required to coordinate mammalian liver regeneration
por: Lu, Li, et al.
Publicado: (2018)

Alternative Splicing Rewires Hippo Signaling Pathway in Hepatocytes to Promote Liver Regeneration
por: Bangru, Sushant, et al.
Publicado: (2018)

Brap regulates liver morphology and hepatocyte turnover via modulation of the Hippo pathway
por: Priest, Christina, et al.
Publicado: (2022)

ER Stress and Autophagy Dysfunction Contribute to Fatty Liver in Diabetic Mice
por: Zhang, Quan, et al.
Publicado: (2015)

Hepatic Huwe1 loss protects mice from non-alcoholic fatty liver disease through lipid metabolic rewiring
por: Feng, William W., et al.
Publicado: (2023)

Aerobic Exercise in the Management of Metabolic Dysfunction Associated Fatty Liver Disease
por: Machado, Mariana Verdelho
Publicado: (2021)

Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
por: Wang, Xiaolin, et al.
Publicado: (2022)

Quality of Life in Adults with Metabolic Dysfunction-Associated Fatty Liver Disease
por: Hwang, Tae-In, et al.
Publicado: (2021)

Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease
por: Lin, Huapeng, et al.
Publicado: (2021)

Implications of metabolic dysfunction associated fatty liver disease in COVID-19
por: Chakraborty, Raja, et al.
Publicado: (2023)

Non-invasive assessment of metabolic dysfunction–associated fatty liver disease
por: Chandra Kumar, C. Vikneshwaran, et al.
Publicado: (2022)

Metabolic dysfunction-associated fatty liver disease in people living with HIV
por: Michel, Maurice, et al.
Publicado: (2023)

Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
por: Song, Byeong Geun, et al.
Publicado: (2023)

Postprandial dysfunction in fatty liver disease
por: Grandt, Josephine, et al.
Publicado: (2023)

Dysfunctional Mechanotransduction through the YAP/TAZ/Hippo Pathway as a Feature of Chronic Disease
por: Cobbaut, Mathias, et al.
Publicado: (2020)

Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease
por: Miao, Lei, et al.
Publicado: (2022)

Metabolic dysfunction–associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study
por: van Kleef, Laurens A., et al.
Publicado: (2021)

Mediterranean diet affects the metabolic outcome of metabolic dysfunction-associated fatty liver disease
por: Xiao, Yuji, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j7ei4a69gnrhv7eh3e25b7o6tj